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Personalized medicineWhile the potential for the application of pharmacogenomics and theranostics to develop personalized
healthcare solutions is enormous, multiple challenges will need to be addressed to get there. Understanding
the complex interactions and detailed characterization of the functional variants of individual ADME (Absorption
Distribution Metabolism Excretion) genes and drug target genes is needed to demonstrate clinical utility, using
both a bottoms-up as well as a top–down approach. Clinical trials need to be designed appropriately so as to
identify not only individual but also population variations. The impact of non-genetic and environmental
factors, epigenetic variations and circadian rhythms on an individual's response need to be assessed to
make pharmacogenomics clinically indicated. More advanced algorithms and appropriate study designs
need to be developed to allow this pipeline to grow and to be used effectively in the clinical setting.
Another challenge lies in the value proposition to the pharmaceutical industry. Fearing the impact of the slice
and dice approach on revenues, companies are going slow on developing pharmacogenomic solutions; yet
many are hedging their bets, amassing huge amounts of single nucleotide polymorphisms (SNP) data. They
are being used as predictors of drug efﬁcacy and safety to zero in on subpopulations that are at risk for either
a bad response or no response in clinical trials, supporting the Fail fast, Fail cheap approach. In addition, the
growth of theranostics is impeded by the fear that the approval of both the diagnostic and the drug would
get delayed. Education of the health care provider, payor, regulator and the patient is also required and an
exercise of change management needs to occur.
Countries such as India should exploit the joint beneﬁt of the reduced cost of tests today, complemented by a
large and a highly genetically diverse population.
© 2013 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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lished by Elsevier B.V. This is an op1. Introduction
Pharmacogenomics has been described differently on various occa-
sions as an area of fevered speculation, intense hype, the path-breaker
of the future — and probably all of them are partly true. In a world that
is becoming increasingly individual centric, patients are demandingen access article under the CC BY-NC-ND license
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quote Sir William Osler, “If it were not for the great variability among in-
dividuals, medicine might as well be a science and not an art” (Frueh,
2005). Pharmacogenomics and theranostics are paving the way for per-
sonalized medicine. While the global pharmaceutical market is approxi-
mately worth $825 billion, up to 40% of the medicines that individuals
take every day are not effective, resulting in losses of up to $400 billion
(India accounts for 20% of the world population, but shares only 2%
of the global pharmaceutical market, primarily for generic drugs)
(Banerjeee, 2011). Even more worrisome is the fact that phase II
success rates are as low as 18%, with 20% of medications failing in the
case of cancer chemotherapy and 23% in the case of patientswith diabe-
tes in phase II trials. The failure rate went up to about 50% in phase III,
with 60% drugs failing due to a lack of efﬁcacy and 21% failing due to
safety concerns (Gitig, 2012). Notably, the number of drugs receiving
approvals in India (by the Central Drugs Standard Control Organization)
per annum following the conduct of clinical trials has decreased from 60
in 2009 (http://www.taxindiaonline.com/RC2/inside2.php3?ﬁlename=
bnews_detail.php3&newsid=15712) to 28 in 2012 (http://cdsco.nic.in/
listofdrugapprovedmain.html). In addition, several medicines have
known side effects, and side effects are considered to be between the
fourth to the sixth biggest cause of avoidable deaths and costly hospital-
ization in the US (Lazarou et al., 1998). The teratogenic risks in human
pregnancy of over 90% of drug treatments approved in the USA in the
last decade are yet to be determined (Banerjeee, 2011). Patients often in-
vest in medications that not only do not yield results owing to the way
individuals respond differentially to different drugs, but may also often
suffer from severe and in some cases irreversible side effects as a result
of the same.
Ten percent of FDA approved drugs (approximately 200 drug labels)
carry pharmacogenomic information in their labels (Zanger, 2010) and
metabolizing enzymes account for 80% of drugs which have
pharmacogenetic data in their label (Brandi et al., 2012). More than
650 drug-related variants have been identiﬁed for their clinical rele-
vance (Banerjeee, 2011).
2. Clinical trials and factors impacting response to therapy
Various factors impact a patient's response to a drug. These include
not only his genotype, but also non-genetic and environmental factors,
including sex, age, diet, lifestyle, and even the intestinal microﬂora.
Epigenetic changes can inﬂuence expression patterns in a time-,
environment- and tissue-dependent manner. Circadian rhythms
also markedly change gene expression patterns of many ADME
genes (over 300 have been identiﬁed to date) thereby affecting phar-
macokinetics and drug response in a time-dependent manner
(Zanger, 2010). Some well-known food–drug interactions, such as
those of grape fruit juice, as well as black tea with the Cytochrome
P450 enzymes or vitamin K rich foods such as broccoli and spinach
with warfarin, can signiﬁcantly impact a patient's response to
drugs (Webb, 2010).
In pharmacogenomic studies, it is important to study not only the
individual SNPs, but haplotypes (statistically associated SNPs or
co-located alleles) as well, making the HapMap an important element
in the diagnosis of disease. The human exome, representing only 1%
of the human genome, accounts for approximately 85% of disease
causing mutations (Dolled-Filhart et al., 2012). With both the speed
of molecular discovery increasing exponentially (in parallel with the
costs), one may feel that we are at the brink of ﬁnding the solutions
to all our problems.
Next-generation rapid sequencing (NGS) technology is likely to
bring the cost of sequencing the human genome from $2.7 billion, to
potentially $ 1000 and global pharmacogenomic testing of an individual
could cost less than $ 100. Interest in pharmacogenomic proﬁling for
drug dosing and drug selection is expected to grow as awareness
increases and costs decrease. Currently, the National Human GenomeResearch Institute (NHGRI) Genome Sequencing Program estimates
that its per-genome cost is $7666. Illumina, whose HiSeq DNA se-
quencing systems produce the bulk of the human genome sequence
reads, is offering the same for as little as $4000 in bulk, while Complete
Genomics is charging $5000 or less. The $10 million Archon X Prize
competition scheduled to occur in September 2013, requires a team to
produce 100humangenome sequences in 30 days or less, at amaximum
cost of $1000 per genome sequence (with an error rate of at least 100 kb
and at least 98% completeness). While we may thus reach the $1000
genome target in the near future, the criticality however lies not only
in sequencing the genome, but in interpreting the data — leading to
the ‘$1000 genome–$1 million interpretome’ paradox (Perkel, 2013).
Global revenues from clinical trials are expected to reach
$32.73 billion in 2015 and to exceed $65 billion by 2021 (India and
China show a Compounded Annual Growth Rate of more than 20%)
(http://www.visiongain.com/Report/973/Pharma-Clinical-Trial-Services-
World-Market-2013-2023). A study across 12 leading pharmaceutical
companies from 1997 to 2011 demonstrated an average spending of
$5.8 billion per drug (Mapes, 2012) and trials account for nearly 60% of
the drug development cost. The Associated Chambers of Commerce and
Industry in India (Assocham) has reported that almost 100 global and
local pharmaceutical companies are conducting clinical trials in India,
resulting in revenues of close to $1.6 billion.With close to 150,000 people
enrolled on the same, the norms for the conduct of these trials are going
to become stricter in the near future. Diseases such as malaria, chicken
guniya, tuberculosis, kala azar (visceral leishmaniasis) and head and
neck cancer are more prevalent in India and trials need to be conducted
to develop therapies to meet the needs of speciﬁc strata of populations
(http://www.business-standard.com/article/economy-policy/govt-
tightening-clinical-trial-norms-112080602002_1.html). An increasing
number of these will be pharmacogenomic trials, involving bio-
markers and companion diagnostics.
2.1. Factors impacting the design of pharmacogenomic trials
Various factors need to be kept in mind while designing
pharmacogenomic trials. It is desirable to choose a genetically
homogenous population as far as possible, as differences in ethnicity
may impact the response to the drug. Appropriate population stratiﬁ-
cation is thus important. While several disease associated biomarkers
have been identiﬁed, it is desirable to assay somemarkers that are not
associated with the disease to maintain a negative control as well.
Irrespective of the type of trial, the biomarker should be evaluated
for predictability and clinical validity. Methodological bias is also an
important consideration, especially in the case of retrospective analyses/
meta-analyses, and the use of a centralizedmeasurement facility for eval-
uating biomarkers is desired; alternatively pooled datasets based on
predeﬁned criteria need to be carefully selected to reduce some types of
bias. It is also desirable to use the drug of the same brand to avoid the
confounding effects of variable bioequivalence (Brandi et al., 2012).
The impact of variations in the prescribed dose over the duration of
the illness would also impact drug response. Metabolic enzymes and
transport proteins may be quantitatively and qualitatively different in
pediatric/elderly populations (EMEA Guideline, 2011) and interpreta-
tions regarding safety and efﬁcacy in such trials need to take due
consideration of the same. Drug–drug interactions occurring during
multi-drug therapy need to be carefully assessed. The deﬁnition of the
disease is also important as different variants of the gene may result
in different diseases. Thus the statistical power of the trial would
depend on the accurate deﬁnition of the disease. The sample size should
be adequate to account for the effects of genotypes/alleles/haplotypes
on the outcome analysis. A larger sample size may be required to assess
adverse drug reactions (ADRs), as compared to the attainment of
response. When multiple mutations are involved in determining the
outcome to be assessed, then a diagnostic test that assesses the pheno-
type is better than the one that assesses the genotype (Adams, 2008).
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Genome-wide (GWA) association studies play a key role in deter-
mining biological genotype–phenotype correlations, and diagnostic
tools are required to effectively translate these into clinical care, simul-
taneously addressing multiple confounding factors— and this is where
the challenge lies. Challenges from a clinical trial perspective for GWA
studies include the small sample sizes resulting from a small population
demonstrating the rare ADRs (http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC30039490/) (addressed through national andmultination-
al consortia) and the difﬁculty of replication of results, a lack of rare or
even less common (b5%) variants on the microarrays (addressed
throughNGS or themapping of the individual's genome), and heteroge-
neity. Finally, advanced algorithms need to be deﬁned which will allow
one to interpret the multifactorial nature of drug response phenotypes,
while correlating data from biological gene networks. Complex genetic
inﬂuences from multiple minor impact genes, entire pathways, or
gene–gene and gene–environment interactions could thus be identiﬁed
(Zanger, 2010).
Variants of drug-metabolizing enzymes impact drug response,
meaning that some individuals are ultra-rapid metabolizers and
others, poor metabolizers of speciﬁc drugs, and the variance directly
impacts the bioavailability of a drug and thus both its efﬁcacy and
its toxicity. For example, 105 variant alleles of CYP2D6, a class of
drug-metabolizing enzymes found in the liver (with one or more
point mutations), have been identiﬁed (Adams, 2008). DNA chip
microarrays, which can screen up to 100,000 SNPs in a few hours, can
be used to diagnose these phenotypic variations. The chip developed by
Affymetrix for example (DMET Plus) covers 1936 genetic variants
(including SNPs and copy number variations) across 231 relevant
genes (including a 100% coverage of PharmaADME “Core ADME
Genes” (32 genes) and 95% coverage of PharmaADME “Core
Markers” (185 variants) (http://www.affymetrix.com/estore/browse/
products.jsp?productId=131412#1_1)). The ‘Core ADME genes’ and
‘CoreMarkers’ are basically a list of a list of genes and genetic biomarkers
that could be screened using today's technology platforms to identify pre-
dictors of pharmacokinetic variability, and thus promise to improve the
drug development process by enabling the design of safer andmore effec-
tive drugs for particular subpopulations. This list was generated by
PharmaADME, an industry–academia effort thatwas launched to develop
a consensus, “Core List” of standardized “evidence based”drugmetaboliz-
ing (ADME) genetic biomarkers that are broadly applicable tomany phar-
maceutical clinical trials and FDA drug submissions (http://
www.pharmaadme.org/joomla/).
Attrition rates in phase II trials have been very high as adequate
efforts have not been invested in clinical validation at the start
(Haberman, 2009). The economics of trials drives the need to fail
fast and fail early (Chew, 2010). Translational research leverages bio-
markers across the stages of the clinical development plan from
target identiﬁcation to assessing the effects of hitting this target on
the pathophysiological mechanism and on determining how altering
this mechanism would affect the clinical outcome — thus deﬁning
the likelihood of success of a candidate drug. Translating research
from bench to bedside has become a criticality. The most frequently
cited success story is that of the HercepTest®/trastuzumab
(Herceptin®) combination from Dako and Genentech/Roche for the
Her2-positive subset of breast cancer patients. Another example is
that of Imatinib (Glivec™, Novartis), a synthetic tyrosine kinase in-
hibitor, which is used in the management of interferon-resistant
chronic myeloid leukemia (CML) and is now, considered as the drug
of choice for metastatic and inoperable gastro intestinal stromal tu-
mors (GIST) (Nair, 2010).
At the end of the day, conclusive interpretations based on data
drawn from the integration of genomics, proteomics, metabolomics,
and epigenetics, and the use of companion diagnostics or theranostics
together are going to help deﬁne the right target population and this,complemented by the appropriate study design, and a well-executed
clinical trial, will help translate research to positive clinical outcomes.
2.3. Leveraging biobanks and databases: collaborating for the future
Biobanks, if linked to Electronic Medical Records, would play a key
role in the translation of genotypic–phenotypic data to clinical therapy
and thus personalized medicine. Challenges that prevail include
informed consent, ensuring patient conﬁdentiality, the issue of donor's
rights, the management of incidental ﬁndings, the need for interopera-
bility between research and clinical databases, the high-power comput-
ing that is required to manage this data, and the related socio-
commercial aspects which makes one wonder whether the $1000
genome sequencing will require a million dollar investment for the
meaningful interpretation of this data (Davies, 2010). Over a billion
dollars have been invested in the past ten years in the biobanking in-
dustry, and the global market for biobanks is forecast to reach over
$22.3 billion by the year 2017 (http://www.prweb.com/releases/
biobanks_cord_blood_banks/stem_cell_banks/prweb8831399.htm).
At least 179 biobanks exist in the US and the Taizhou project in China
is expected to cover the entire population of the country (http://
www.reportlinker.com, 2009). Kaiser's Research ProgramonGenes, Envi-
ronment and Health (RPGEH) attempts to triage genetic, environmental
and medical information, to allow for better interpretation of health
outcomes and has also resulted in the largest DNA biobank in the
US. Similarly, Genethon (Paris) is one of Europe's largest cell and tissue
repositories (Scott et al., 2012). Important biobanking projects in
Asia include NUS-NUH Tissue Repository, SingHealth Tissue Reposi-
tory, Singapore, UMCRI Tumour Tissue Bank, Cryocord Premiere stem
cell bank, Malaysia, RIKSEN Bioresource center cell bank, Japan;
Institutional Tissue Bank Fudan University, China Cord Blood Corpora-
tion and China and National Biobank of Korea (NBK). Some of the
biobanks in India include NIMHANS, Bangalore (the brain biobank),
ACTREC, Mumbai (cancer biobank), ORBO (Organ Retrieval Banking
Organization), AIIMS, New Delhi, the National Repository for Cell Lines/
Hybridomas, NCCS, Pune and the Mycobacterial Repository, JALMA, Agra
(Ravishankar, 2012, http://www.biospectrumasia.com/biospectrum/
opinion/1750/biobanking-attractive-prospects-asia).
Companies such as Genset SA (recently acquired by Serono SA),
DNAPrint, genomics, deCODE genetics, Genaissance Pharmaceuticals
Inc., and Oxagen Ltd., as well as pharmas such as GlaxoSmithKline and
Novartis AG invested in building SNP databases. The SNP Consortium
has published more than a million SNPs on the web (Branca, 2002). The
$120 million Human Genome Project involving 700 scientists from the
US, Canada, China, Japan, Nigeria and Kenya recently sequenced the com-
plete DNAmaterial of more than 1000 people from 14 population groups
in Europe, Africa, East Asia and the Americas. Scientists have identiﬁed
38 million variations in the DNA accounting for about 98% of all the esti-
mated human variation in the world (htttp://online.wsj.com/article/
SB10001424052970204707104578090863855010972.html). The Cancer
GenomeAtlas is an effort to collectmore than 20,000 tissue samples from
more than 20 cancers, and identify cascades of genetic changes that give
rise to tumor growth (http://cancergenome.nih.gov).
The Indian Genome Variation (IGV) Consortium, a government-
funded collaborative program among six laboratories of the Council of
Scientiﬁc and Industrial Research (CSIR) aims to provide data on vali-
dated SNPs in over a thousand genes in 15,000 individuals (Dhar and
Joseph, 2012). HUGO (Human Genome Organization) the ﬁrst-ever
human genome sequencing project in India, driven by scientists at the
Institute of Genomics and Integrative Biology (IGIB), New Delhi has
been completed (BioSpectrum http://www.biospectrumindia.com/
biospecindia/news/156732/indias-r-d-the-future-forward). The Indian
Council of Medical Research (ICMR) has recently set up a new task
force on pharmocogenomics to focus on speciﬁc research topics in
the ﬁeld of pharmacogenomics and will also work on the develop-
ment of an ‘Indian pharmacogenomics chip’ (http://www.thehindu.
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As more and information becomes available, the need for accessibility
of information becomes important. Pharmacogenomics Knowledgebase
(www.PharmGKB.org) is a publicly available repository for pharma-
cogenetic and pharmacogenomic data and serves as an interactive tool
for researchers investigating how genetic variation effects drug response
and has been funded by the NIH (Mc Donagh et al., 2011).
2.4. Cutting it ﬁne — stratiﬁcation, a key to personalized medicine
As clinical utility is demonstrated and the beneﬁts of pharma-
cogenomics start to be realized for both individuals and health care
systems, issues of data ownership andmultiple commercial implications
and other ethical issues arising from clinical applications come into the
picture. While the ‘slice-and-dice’ approach (involving market segmen-
tation as a result of developing personalized therapies) raises obvious
commercial concerns in the pharma industry, and also raises ethical
issues about racial proﬁling, this approach obviously stands to beneﬁt
key segments of society owing to their genetic differentiation. For
example, heart failure rates are high in African-Americans, as they
appear to have a much lower response rate to angiotensin-converting
enzyme (ACE) inhibitors, the conventional therapy for heart disease.
The drug BiDil, was developed to treat congestive heart failure in a
deﬁned sub-population (http://www.scientiﬁcamerican.com/article.
cfm?id=race-in-a-bottle&print=true(9/21/2009). Another example of
a selective response of sub-populations is that of “Ancestral North
Indians” (ANI), which are genetically close to Middle Easterners, Central
Asians, and Europeans, as compared to “Ancestral South Indians” (ASI),
which are as distinct from ANI and East Asians, as they are from
each other. It has been reported that up to 30 essential drugs are not
effective on 13% of Northern India's population (Reich et al., 2009). Com-
munity intervention design, in which a region or a hospital performing
pharmacogenetic analyses are compared to other region(s) and hospi-
tal(s) that are not performing such tests, would also help contribute to
such analysis (Brandi et al., 2012). Thus, one could visualize that despite
stratiﬁcation of a huge and a genetically diverse Indian population, each
segment would still represent a large enough slice to draw commercial
beneﬁts, and yet beneﬁt society as well. The criticality would be to
make this affordable to the masses and yet proﬁtable to the industry,
especially in a geography where there is very little healthcare coverage.
2.5. Pharmacogenomics — India, a key destination
Various companies globally, including those in India, have started
investing in pharmacogenomics, such as Xcode Lifesciences (which
uses InDNA technology to provide solutions for lifestyle-related
diseases such as coronary, diabetes and obesity using saliva samples,
https://xcode.in/), NutraGene (which launched the country's ﬁrst
commercial Type 2 Diabetes Genetic Scan based on a buccal (cheek)
swab sample— individual tests cost below Rs7500, and include com-
plimentary genetic counseling, http://www.nutragene.com/), Acton
Biotech, Pune (which offers genetic tests to predict response from
chemotherapy drugs such as geﬁtinib and cetuximab), OncQuest
Laboratories, Mumbai (which brought Imatinib Resistance Mutation
Analysis for chronic myeloid leukemia to the market and has launched
several pharmacogenetic tests including those for Irinotecan toxicity,
warfarin dosing and Clopidogrel dosing, www.oncquest.net/), TCG
Life Sciences, Advinus Therapeutics and Jubilant Biosys, Bangalore.
Avesthagen, Bangalore is running the ﬁve-year, $32 million
AVESTAGENOME Project. AVESTAGENOME is a system biology-
based study of the Parsi population (a genetically homogenous
population of about 69,000 people) to determine the genetic basis of
longevity and age-related disorders (Murarka, 2012). Thus, India is
rapidly building therapeutic, diagnostic and infrastructure capabilities
in this space, and various companies (http://www.actonbiotech.com/pharmacogenomics) supporting the same have been established.
Ganit Labs is a genome sequencing and translational genomics lab,
based out of Bangalore (http://www.ganitlabs.in/), ABC Genomics,
based out of Lucknow provides low cost in situ synthesized custom
microarrays for all available sequenced genomes (http://www.
abcgenomics.com/), Geneombio Technologies, based out of Pune,
provides predictive genetics and pharmacogenomic services, in-
cluding gene based prediction for genetic susceptibility towards
major life style diseases such as osteoporosis, insulin resistance
and cardiovascular disorders and also undertakes drug toxicity
studies based on speciﬁc CYP and/or pathway gene analysis
(http://www.geneombiotechnologies.com/about-us.php), and Xcelris
Genomics (Bangalore), provides “application focused” research in Next
Generation Genomics (http://www.xcelrisgenomics.com/). Sandor Pro-
teomics is a contract research and diagnostic center based out of Hyder-
abad. It focuses on the discovery of biomarkers pertaining to human
health and agriculture and has been accredited by NABL (National
Accreditation Board of Laboratories) as a diagnostic center for inborn
metabolic errors (http://www.sandor.co.in/aboutus-proteomics.html)
whereas Sandor Medicaids provides logistics solutions to manufacturers
in themedical device and hospital supplies industries that look for a tem-
perature sensitive environment for their products (http://www.sandor.
co.in/aboutmedicaids.html). Mitra Biotech, based in Bangalore, is a
Indo-US translational biology company focused on developing personal-
ized treatment options for cancer. Jai Health launched Jai-Heart, the ﬁrst
genomic based risk estimation solution for heart disease developed spe-
ciﬁcally for the Indian, South-east Asian and Middle East population,
based on a simple saliva test (Vyas, 2012).
However, to realize improved outcomes and cost savings, one needs
to implement not only the scientiﬁc advances discussed above but
changes to health care systems and practice patterns as well. Change
management, patient and physician education, competitive pricing,
regulations to ensure appropriate informed consent processes, privacy
protection concerning the use of genotype information in multiple
studies and data ownership, are critical to support the growth of this
domain to beneﬁt India. Key institutes, such as the CSIR-Institute of Ge-
nomics & Integrative Biology (IGIB), based in Delhi, a premier Institute
of Council of Scientiﬁc and Industrial Research (CSIR), are also engaged
in research on areas such as genomics, molecular medicine, bioinfor-
matics, proteomics and environmental biotechnology.
India has recently established the Translational Health Science and
Technology Institute (THSTI) at Gurgaon, Haryana as an emerging
health biotech science consortium with the intent of translating
science and technology into clinical practice (http://www.
clinicalresearchsociety.org/translationalmedicine). Aravind K. Tripathi,
senior researcher, Cancer Proﬁling & Pharmacogenomics Division,
Acton Biotech has reported the lack of exposure of molecular biology
among doctors, the high costs of these tests as compared to the cost of
treatment, longer turnaround times, the lack of bedside technologies,
lack of skilled manpower and the smaller market size; and hence the
lack of investment inmarketing these tests, as someof the key challenges
impacting the growth of pharmacogenomics in India (Jahanara, 2010).
Clinical trials in India are regulated by the Drugs and Cosmetics
Act 1940, amended 2005, and must also comply with the Ethical
Guidelines for Biomedical Research on Human Subjects 2000
(adopted by the Indian Council of Medical Research, ICMR) and the
Good Clinical Practices (GCP) 2001 guidelines (adopted by theMinistry
of Health). All research proposals for human trials must be approved by
an Institutional Ethics Committee (IEC) and must obtain consent from
research subjects. Accordingly, each IEC must respect the standard op-
erating procedures stipulated by the ICMR guidelines. The Department
of Biotechnology (DBT) mandates that for a pharmacogenomic study
to be conducted in India it should be of national relevance, and to
meet this requirement, the disease under consideration should have
a high prevalence in India. In addition, it is necessary that the drug
under consideration should be a widely-used drug for the treatment
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spond to the drug or do not elicit adverse reactions should be high.
While submitting the proposal to the DBT, it is extremely important
to assess whether there may be any underlying clinical heterogene-
ity in the manifestation of the disease and if so, it is important to out-
line how it would be handled in the study (http://dbtindia.nic.in/
uniquepage.asp?id_pk=41).
3. Conclusion
Rare but severe adverse events have been a major cause for drug
withdrawals after FDA approval, resulting in losses of up to a billion US
dollars for a pharma company. Oncology is one of the most promising
therapeutic areas in pharmacogenomics, owing to the enormous tumoral
genomic variability. As noted above, the success of pharmacogenomic
trials will require a blend of trained clinical workforce, validated genetic
tests, payorswilling to fund pre-treatment tests, accessibility, and change
management. The application of pharmacogenomics and theranostics
could well be the key to developing patient-focused, cost effective thera-
pies and truly translating the vision of personalized medicine from a
dream to reality, not only in the United States, but also in India and the
vast reaches of the developing world where the need for cost efﬁcient
and effective therapy is great. The healthcare beneﬁts that can be lever-
aged even from a stratiﬁed approach, wherein patients are segmented
based on genotypic/phenotypic variations, are signiﬁcant, as the net pop-
ulation of India itself is more than 1.2 billion. While deﬁning appropriate
study designs and establishingwell deﬁned algorithmsmay seem like tall
challenges, evidentiary requirements, like medical advice, continually
change, and an important policy issue is what constitutes adequate
proof of clinical utility, particularly in the developing world where inno-
vation promises to vastly improved outcomes. Well deﬁned regulations,
establishing a skilled work force, educating the patient, healthcare pro-
vider and the payor, providing a focus on investment, cost effective solu-
tions and ensuring patient safety and privacywill be key drivers to ensure
the full recognition of the potential of pharmacogenomics and the accep-
tance of the personalized medicine approach in developing countries
such as India. Stakeholder collaboration of payors, providers, patients,
care delivery institutions, and government may be increasingly impor-
tant to achieving the shared goals of improved outcomes and cost
savings.
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